TABLE 1.

Levels of soluble integrin β2 in the peritoneal fluid are not altered by the absence of MMP-9 or by ADAM10 or ADAM17 myeloid deficiency

Integrin β2 levels in the peritoneal fluid (units/ml) collected 3 days following thioglycollate injection or 3 days following thioglycollate and an additional 4-h post-injection of LPS were measured by ELISA. The means ± S.E. are shown for the indicated number of mice. ND indicates not determined.

Enzyme genotype	Soluble integrin β2 in 3-day post-thioglycollate peritoneal fluid	n	Soluble integrin β2 in 3-day post-thioglycollate also with 4-h LPS peritoneal fluid
Wild type MMP-9	29.73 ± 2.74	4	79.07 ± 3.67
MMP-9 null	29.97 ± 7.82	4	72.85 ± 10.6
Wild type ADAM10	28.33 ± 3.28	5	ND
Myeloid-deficient ADAM10	28.05 ± 3.74	5	ND
Wild type ADAM17 hematopoietic chimeras	37.86 ± 3.71	5	69.32 ± 4.87
ADAM17-deficient hematopoietic chimeras	36.36 ± 2.12	5	66.32 ± 4.18